Latest News and Updates

* (R) = Regulatory press releases

Aug 21, 2025

(R) Cantargia publishes half-year report 2025

Aug 18, 2025

(R) Cantargia appoints Dr Hilde Steineger as Chief Executive Officer

Aug 12, 2025

Invitation to the presentation of Cantargia’s H1 2025 report

Jul 17, 2025

(R) Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)

Jul 16, 2025

Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer

Jul 15, 2025

(R) Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical

Jun 17, 2025

(R) Cantargia signs SEK 50 million financing facility agreement, extending cash runway into 2026 and providing operating flexibility to drive strategic plans

Jun 11, 2025

Cantargia’s nadunolimab antibody awarded US FDA Fast Track Designation

May 19, 2025

Cantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation

May 15, 2025

(R) Bulletin from the Annual General Meeting in Cantargia AB

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Cantargia publishes half-year report 2025

(R) Cantargia appoints Dr Hilde Steineger as Chief Executive Officer

Invitation to the presentation of Cantargia’s H1 2025 report

(R) Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)

Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer

(R) Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical

(R) Cantargia signs SEK 50 million financing facility agreement, extending cash runway into 2026 and providing operating flexibility to drive strategic plans

Cantargia’s nadunolimab antibody awarded US FDA Fast Track Designation

Cantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation

(R) Bulletin from the Annual General Meeting in Cantargia AB

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07